NEW YORK--(BUSINESS WIRE)--LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of ChemGenex Pharmaceuticals (ASX:CXS) (Pink Sheets:CXSPY), an oncology focused biopharmaceutical company developing small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs.
